POM3
PreclinicalSmall molecule
POM3 is one of 16 small molecule programs targeting Hypertriglyceridemia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hypertriglyceridemia
#DrugCompanyPhaseTrials
1Lopid
PfizerApproved
Crestor
AstraZenecaApproved
Cipro
BayerApproved
Selzentry
GSKApproved
Zocor
OOrganon and Co
Approved
Topamax
WWim Janssens
Approved
Tryngolza (autoinjector)
Ionis PharmaceuticalsPhase 3
Redemplo
Arrowhead PharmaceuticalsPhase 3
Avandia
Jazz PharmaceuticalsPreclinical
Repatha
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for POM3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PProvident Clinical Research